SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-03-06
DOI
10.3389/fphar.2018.00194
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatobiliary Cancers
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway
- (2016) L.-K. Ran et al. CLINICAL CANCER RESEARCH
- SIRT6 Depletion Suppresses Tumor Growth by Promoting Cellular Senescence Induced by DNA Damage in HCC
- (2016) Namgyu Lee et al. PLoS One
- Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway
- (2016) Na-Na Tao et al. Oncotarget
- Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters
- (2015) So-Young Chun et al. BIOMEDICINE & PHARMACOTHERAPY
- Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics
- (2015) Giovanna Sociali et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer
- (2015) Yoko Azuma et al. JOURNAL OF SURGICAL ONCOLOGY
- Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway
- (2015) C-L Song et al. ONCOGENE
- Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma
- (2014) YVONNE Y.Y. OR et al. Molecular Medicine Reports
- SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer
- (2013) Mattaka Khongkow et al. CARCINOGENESIS
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics
- (2013) Yewei Liu et al. Protein & Cell
- Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
- (2012) Che-Ming Jack Hu et al. BIOCHEMICAL PHARMACOLOGY
- NAMPT is essential for the G-CSF–induced myeloid differentiation via a NAD+–sirtuin-1–dependent pathway
- (2009) Julia Skokowa et al. NATURE MEDICINE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus–endemic area
- (2007) Kyung Woo Park et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search